Other immunosuppressive agents for focal segmental glomerulosclerosis

Seminars in Nephrology

Volumn 23, Issue 2, 2003, Pages 242-248

  Ponticelli, Claudio ^a   Passerini, Patrizia ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; LOW DENSITY LIPOPROTEIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE;

APHERESIS; CANCER RISK; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; FOLLOW UP; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; NEPHROTIC SYNDROME; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; RECURRENCE RISK; REVIEW; STATISTICAL ANALYSIS; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME;

EID: 0037353169     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1053/snep.2003.50023     Document Type: Review

References (47)

1. Burgess E: Management of focal segmental glomerulosclerosis: Evidence-based recommendations. Kidney Int 55: S26-S32, 1999 (suppl 70)
2. Beaufils H, Alphonse JC, Guedon J, et al: Focal glomerulosclerosis: Natural history and treatment. Nephron 21:75-85, 1978
3. Cameron JS, Turner DR, Ogg CS, et al: The long-term prognosis of patients with focal and segmental glomerulosclerosis. Clin Nephrol 10:211-218, 1978
4. Velosa JA, Holley KE, Torres VE, et al: Significance of proteinuria on the outcome of renal function in patients with focal segmental glomerulosclerosis. Mayo Clin Proc 58:568-577, 1983
5. Korbet SM, Schwartz MM, Lewis EJ: Primary focal segmental glomerulosclerosis. Clinical course and response to therapy. Am J Kidney Dis 23:773-783, 1998
6. Cameron JS: The long-term outcome of glomerular diseases, in Schrier RN, Gottschalk CW (eds): Diseases of the Kidney (ed 2). Boston, Little Brown, 1992, pp 895-958
7. Siegel NJ, Gaudio KM, Krassner LS, et al: Steroid-dependent nephrotic syndrome in children: Histopathology and relapses after cyclophosphamide treatment, Kidney Int 19:454-459, 1981
8. Schulman SL, Kaiser BA, Polinsky MS, et al: Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: Superiority of response to corticosteroid therapy over histopathologic patterns. J Pediatr 113:996-1001, 1988
9. Pei Y, Cattran D, Delmore T, et al: Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Am J Med 82:938-944, 1987
10. Banfi G, Moriggi M, Sabadini E, et al: The impact of prolonged immunosuppression on the outcome of idiopathic focal segmental glomerulosclerosis with nephrotic syndrome in adults. Clin Nephrol 36:53-59, 1991
11. Agarwal SK, Dash SC, Tiwari SC, et al: Idiopathic adult focal segmental glomerulosclerosis: A clinicopathologic study and response to steroid. Nephron 63:168-171, 1993
12. Rydel JJ, Korbet SM, Borok RZ, et al: Focal segmental glomerular sclerosis in adults: Presentation, course and response to therapy. Am J Kidney Dis 25:534-542, 1995
13. Ponticelli C, Villa M, Banfi G, et al: Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis? Am J Kidney Dis 34:618-624, 1999
14. Meyrier A: Treatment of primary focal segmental glomerulosclerosis. Nephrol Dial Transplant 14:74-78, 1999 (suppl 3)
15. Ponticelli C, Banfi G: Focal and segmental glomerulosclerosis, in Ponticelli C, Glassock RJ (eds): Treatment of Primary Glomerulonephritis. Oxford, Oxford University Press, 1997, pp 108-145
16. Tarshish P, Tobin JN, Bernstein J, et al: Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. Pediatr Nephrol 10:590-593, 1996
17. Rennert WP, Kala UK, Jacobs D, et al: Pulse cyclophosphamide for steroid-resistant focal segmental glomerulosclerosis. Pediatr Nephrol 13:113-116, 1999
18. Gulati S, Kher V: Intravenous pulse cyclophosphamide - a new regime for steroid resistant focal segmental glomerulosclerosis. Indian Pediatr 37:141-148, 2000
19. Mendoza SA, Reznik VM, Griswold WR, et al: Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents. Pediatr Nephrol 4:303-307, 1990
20. Waldo FB, Benfield MR, Kohaut EC: Methylprednisolone treatment of patients with steroid-resistant nephrotic syndrome. Pediatr Nephrol 6:503-505, 1992
21. Guillot AP, Kim MS: Pulse steroid therapy (PTS) does not alter the course of focal segmental glomerulosclerosis (FSGS). Am J Kidney Dis 4:276, 1993
22. Tune BM, Kirpekar R, Sibley RK, et al: Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: A long-term follow-up. Clin Nephrol 43:84-88, 1995
23. Aviles DH, Irwin KC, Dublin LS, et al: Aggressive treatment of severe idiopathic focal segmental glomerulosclerosis. Pediatr Nephrol 13:298-300, 1999
24. Hary P, Bagga A, Jindal N, et al: Treatment of focal glomerulosclerosis with pulse steroids and oral cyclophosphamide. Clin Nephrol 16:901-905, 2001
25. Watson AR, Rance CP, Bain J: Long term effects of cyclophosphamide on testicular function. Br Med J 291:1457-1460, 1985
26. Callis L, Nieto J, Vila A, et al: Chlorambucil treatment in minimal lesion nephrotic syndrome: A reappraisal of its gonadal toxicity. J Pediatr 97:653-656, 1980
27. Bartosh SM: The use of mycophenolate mofetil in children with nephrotic syndrome. J Am Soc Nephrol 10:95A, 1999 (abstr)
28. Montane B, Abitbol C, Paredes A, et al: Micophenolate mofetil (MMF) treatment in steroid resistant relapsing nephrotic syndrome (NS) of childhood. J Am Soc Nephrol 10:11A, 1999 (abstr)
29. Al-Lehbi MA, Al-Mutairi KA, Al-Meshari OI, et al: Mycophenolate mofetil (MMF) in steroid resistant focal segmental glomerulosclerosis (FSGS) (cyclosporine dependent or resistant). J Am Soc Nephrol 10:94A, 1999 (abstr)
30. Matalon A, Valery A, Appel GB: Treatment of focal segmental glomerulosclerosis. Semin Nephrol 20:309-317, 2000
31. Choi MJ, Eustace JA, Gimenez LF, et al: Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 61:1098-1114, 2002
32. Dantal J, Bigot E, Boger SW, et al: Effect of plasma protein adsorption on protein excretion in kidney transplant recipient with recurrent nephrotic syndrome. N Engl J Med 330:7-14, 1994
33. Savin VJ, Sharma R, Sharma M, et al: Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 334:878-883, 1996
34. Sharma M, Sharma R, McCarthy ET, et al: "The FSGS factor." Enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma. J Am Soc Nephrol 10: 552-561, 1999
35. Vecsei AK, Muller T, Schratzberger EC, et al: Plasmapheresis-induced remission in otherwise therapy-resistant FSGS. Pediatr Nephrol 16:898-900, 2001
36. Ginsburg DS, Dau P: Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis. Clin Nephrol 48:282-287, 1997
37. Mitwalli AH: Adding plasmapheresis to corticosteroids and alkylating agents: Does it benefit patients with focal segmental glomerulosclerosis? Nephrol Dial Transplant 13:1524-1528, 1998
38. Feld SM, Figueroa P, Savin V, et al: Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys. Am J Kidney Dis 32:230-237, 1998
39. Haas M, Godfrin Y, Oberbauer R, et al: Plasma immunadsorption treatment in patients with primary focal and segmental glomerulosclerosis. Nephrol Dial Transplant 13:2013-2016, 1998
40. Candiano G, Musante L, Carraro M, et al: Apolipoproteins prevent glomerular albumin permeability induced in vitro by serum from patients with focal segmental glomerulosclerosis. J Am Soc Nephrol 13:143-150, 2001
41. Kasiske BL, Velosa JA, Halstenson CE, et al: The effects of lovastatin in hyperlipidemic patients with nephrotic syndrome. Am J Kidney Dis 15:8-15, 1990
42. D'Amico G, Gentile MC, Manna G, et al: Effect of vegetarian soy diet on hyperlipidemia in nephrotic syndrome. Lancet 339:1131-1134, 1992
43. Hattori M, Ito K, Kawaguchi H, et al: Treatment with a combination of low-density lipoprotein apheresis and pravastatin of a patient with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis. Pediatr Nephrol 7:196-198, 1993
44. Iawahori T, Yoshida M, Sugiura M, et al: Excellent antiproteinuric effect by LDL apheresis in a case with severe renal dysfunction due to focal segmental glomerulosclerosis. Nippon Jinzo Gakkai Shi 38:91-97, 1996
45. Yokoyama K, Sakai S, Sigematsu T, et al: LDL adsorption improves the response of focal glomerulosclerosis to corticosteroid therapy. Clin Nephrol 50:1-7, 1998
46. Muso E, Mune M, Fujii Y, et al: Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron 89:408-415, 2001
47. Ponticelli C, Zucchelli P, Imbasciati E, et al: Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 310:946-950, 1984